

9531527

To: (10)(2e) [redacted] (10)(2e) [redacted]@hoyngrkh.com]
Cc: (10)(2e) [redacted] (10)(2e) [redacted]@minvws.nl]; (10)(2e) [redacted] (10)(2e) [redacted]@minvws.nl]; (10)(2e) [redacted]
From: (10)(2e) [redacted]
Sent: Wed 6/10/2020 5:11:51 PM
Subject: Re: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine(AZD 1222) in Europe (ex-UK).

We wachten het af.

(10)(2e) [redacted]
 (10)(2e) [redacted] KPMG (10)(2e) [redacted]
 (10)(2e) [redacted]

> Op 10 jun. 2020 om 19:09 heeft (10)(2e) [redacted] <(10)(2e) [redacted]@hoyngrkh.com> het volgende geschreven:

>
 > Geen probleem (10)(2e) [redacted] stuur het maar wanneer het er is.
 > Groet,
 > (10)(2e) [redacted]

>
 > Verstuurd vanaf mijn iPhone

>> Op 10 jun. 2020 om 19:08 heeft (10)(2e) [redacted] <(10)(2e) [redacted]@minvws.nl> het volgende geschreven:

>>
 >> Hallo (10)(2e) [redacted] en (10)(2e) [redacted]
 >>
 >> Blijkbaar hanteert AZ de deadline iets minder strak dan we zouden mogen verwachten. Zie onderstaande en hoe de Fransen voorstellen er mee om te gaan dat het later is (gezien meeting tussen de ministers om 21u), erg fijn als jullie wanneer we eea krijgen er nog een blik op kunnen werpen.

>> Groet, (10)(2e) [redacted]

>>
 >> -----Oorspronkelijk bericht-----
 >> Van: (10)(2e) [redacted]

>> Verzonden: woensdag 10 juni 2020 19:06
 >> Aan: (10)(2e) [redacted] (10)(2e) [redacted]@pm.gouv.fr>
 >> CC: (10)(2e) [redacted] <(10)(2e) [redacted]@minvws.nl>; (10)(2e) [redacted] <(10)(2e) [redacted]@lgf.finances.gouv.fr>
 >> Onderwerp: RE: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).
 >> Gevoeligheid: Vertrouwelijk

>> Thank you for your reply, I will inform our advisors Kind regards, (10)(2e) [redacted]

>> -----Oorspronkelijk bericht-----
 >> Van: (10)(2e) [redacted] <(10)(2e) [redacted]@pm.gouv.fr>

>> Verzonden: woensdag 10 juni 2020 19:05
 >> Aan: (10)(2e) [redacted] <(10)(2e) [redacted]@minvws.nl>
 >> CC: (10)(2e) [redacted] <(10)(2e) [redacted]@minvws.nl>; (10)(2e) [redacted] <(10)(2e) [redacted]@lgf.finances.gouv.fr>
 >> Onderwerp: RE: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).
 >> Gevoeligheid: Vertrouwelijk

>> We have a call in 30 min with them, no news for the moment
 >>
 >> Thus we preparing a wording
 >>
 >> We also preparing a separating sheet comparing wording and your point (NL, DE, IT + KOM)

>> best regards

>>
 >> (10)(2e) [redacted] Secrétariat général pour l'investissement 32, rue de Babylone
 >> 75007 PARIS
 >> (10)(2e) [redacted]

>>
 >>
 >>
 >>
 >> -----Message d'origine-----

9531527

>> De : (10)(2e) <(10)(2e)> @minvws.nl> Envoyé : mercredi 10 juin 2020 18:51 À : (10)(2e) <(10)(2e)>
 >> Cc : (10)(2e) <(10)(2e)> @pm.gouv.fr>
 >> Obj : RE: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).
 >> Critère de diffusion : Confidentiel
 >>
 >> Dear (10)(2e)
 >>
 >> Do you have any indication at what time AZ will have a final proposition for today?
 >>
 >> Best wishes, (10)(2e)
 >>
 >> -----Oorspronkelijk bericht-----
 >> Van: (10)(2e) <(10)(2e)> @pm.gouv.fr>
 >> Verzonden: dinsdag 9 juni 2020 14:12
 >> Aan: (10)(2e) <(10)(2e)> @minvws.nl>
 >> CC: (10)(2e) <(10)(2e)> @minvws.nl>; (10)(2e) <(10)(2e)> @igf.finances.gouv.fr>
 >> Onderwerp: RE: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).
 >> Gevoeligheid: Vertrouwelijk
 >>
 >> Ok
 >> We met AZ @7pm and we have a briefing with our lawyers @4:30 Would be great if you send us your comments before 4pm In any case we keep you informed "online"
 >>
 >> Best regards
 >>
 >> (10)(2e) Secrétariat général pour l'investissement 32, rue de Babylone
 >> 75007 PARIS
 >> (10)(2e)
 >>
 >>
 >> -----Message d'origine-----
 >> De : (10)(2e) <(10)(2e)> @minvws.nl> Envoyé : mardi 9 juin 2020 14:06 À : (10)(2e) <(10)(2e)>
 >> Cc : (10)(2e) <(10)(2e)> @pm.gouv.fr>
 >> Obj : RE: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).
 >> Critère de diffusion : Confidentiel
 >>
 >> Dear (10)(2e)
 >>
 >> Thank you for your initiative to talk to AZ this afternoon. We will share our points this afternoon so you can involve them in your discussion. In general I think we touch upon the same topics, perhaps the suggestions which are currently being drafted by our legal and financial advisors can be helpful to you.
 >>
 >> Kind regards, (10)(2e)
 >>
 >> -----Oorspronkelijk bericht-----
 >> Van: (10)(2e) <(10)(2e)> s.1.2e@pm.gouv.fr>
 >> Verzonden: dinsdag 9 juni 2020 13:08
 >> Aan: (10)(2e) <(10)(2e)> @bmg.bund.de>
 >> CC: (10)(2e) <(10)(2e)> @igf.finances.gouv.fr>; (10)(2e) <(10)(2e)> @minvws.nl>; (10)(2e) <(10)(2e)> @sanita.it>; (10)(2e) <(10)(2e)> @unicat.it>; (10)(2e) <(10)(2e)> @unicat.it>; (10)(2e) <(10)(2e)> s.1.2e@minvws.nl>
 >> Onderwerp: RE: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).
 >> Gevoeligheid: Vertrouwelijk
 >>
 >> Dear (10)(2e)
 >>
 >> Thanks for your help
 >> Of course we take your point and keep close contact with all of you.
 >> May be Angelique and Walter or Giuseppe may give us your critical points
 >>
 >> Best regards
 >>

9531527

>> [REDACTED] (10)(2e)
 >> [REDACTED] (10)(2e) Secrétariat général pour l'investissement 32, rue de Babylone
 >> 75007 PARIS
 >> [REDACTED] (10)(2e)
 >>
 >>
 >>
 >> -----Message d'origine-----
 >> De : [REDACTED] (10)(2e) <[REDACTED] (10)(2e)@bmg.bund.de> Envoyé : mardi 9 juin 2020 13:02 À : [REDACTED] (10)(2e)
 >> <[REDACTED] (10)(2e)@pm.gouv.fr>
 >> Cc : [REDACTED] (10)(2e); [REDACTED] (10)(2e)@igf.finances.gouv.fr>; [REDACTED] (10)(2e)@minwv.nl' <[REDACTED] (10)(2e)@minwv.nl>; [REDACTED] (10)(2e)@sanita.it'
 >> <[REDACTED] (10)(2e)@sanita.it>; [REDACTED] (10)(2e)@unicatt.it' <[REDACTED] (10)(2e)@unicatt.it>; [REDACTED] (10)(2e)@minwv.nl' <[REDACTED] (10)(2e)@minwv.nl> Objet :
 >> AW: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).
 >> Critère de diffusion : Confidentiel
 >>
 >> Cher [REDACTED] (10)(2e)
 >>
 >> Here are our contacts with AstraZeneca.
 >>
 >> On your critical points:
 >> [REDACTED] (10)(2e)
 >>
 >> In any other points, we have no concerns with your comments and proposals.
 >>
 >> [REDACTED] (10)(2e) [REDACTED] (10)(2e)
 >> In our view, the development of a coronavirus vaccine is a very exceptional situation not directly comparable with normal drug development. This situation requires different roles of industry and governments as usual.
 >>
 >> Cordially, [REDACTED] (10)(2e)
 >>
 >> [REDACTED] (10)(2e) [REDACTED] (10)(2e)
 >>
 >> and
 >> [REDACTED] (10)(2e)
 >>
 >> T: [REDACTED] (10)(2e) [REDACTED] (10)(2e)@astrazeneca.com
 >>
 >> Mit freundlichen Grüßen
 >> Im Auftrag
 >>
 >> [REDACTED] (10)(2e)
 >>
 >> _____
 >>
 >> Leiter der Abteilung 1 „Arzneimittel, Medizinprodukte und Biotechnologie“ Bundesministerium für Gesundheit
 >>
 >> Friedrichstraße 108, 10117 Berlin
 >>
 >> Postanschrift: 11055 Berlin
 >> Tel. [REDACTED] (10)(2e)
 >> Fax [REDACTED] (10)(2e)
 >> [REDACTED] (10)(2e)@bmg.bund.de
 >>
 >> [https://urldefense.com/v3/_http://www.bundesgesundheitsministerium.de_!!E1R1dd1bLLODIQ4IRJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqIUtjLay0\\$](https://urldefense.com/v3/_http://www.bundesgesundheitsministerium.de_!!E1R1dd1bLLODIQ4IRJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqIUtjLay0$)
 >>
 >> [https://urldefense.com/v3/_http://www.twitter.com/BMG_Bund_!!E1R1dd1bLLODIQ4IRJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqIUdfGVy5s\\$](https://urldefense.com/v3/_http://www.twitter.com/BMG_Bund_!!E1R1dd1bLLODIQ4IRJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqIUdfGVy5s$)
 >>
 >> [https://urldefense.com/v3/_http://www.facebook.com/BMG.Bund_!!E1R1dd1bLLODIQ4IRJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqIUdRxl8\\$](https://urldefense.com/v3/_http://www.facebook.com/BMG.Bund_!!E1R1dd1bLLODIQ4IRJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqIUdRxl8$)
 >>
 >> Hinweis zu externen Links: Auf Art und Umfang der übertragenen bzw. gespeicherten Daten hat das BMG keinen Einfluss.

9531527

>> Der Schutz Ihrer Daten ist uns wichtig. Nähere Informationen zum Umgang mit personenbezogenen Daten im BMG können Sie der Datenschutzerklärung auf [https://urldefense.com/v3/_https://www.bundesgesundheitsministerium.de/datenschutz.html_!!E1R1dd1bLLODIQ4IRJewxWOWTLnzG_h21oDKeprEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fglU9fgpgTY\\$](https://urldefense.com/v3/_https://www.bundesgesundheitsministerium.de/datenschutz.html_!!E1R1dd1bLLODIQ4IRJewxWOWTLnzG_h21oDKeprEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fglU9fgpgTY$) entnehmen.

>>
>>
>>

>> -----Ursprüngliche Nachricht-----

>> Von: (10)(2e) (10)(2e) @pm.gouv.fr]

>> Gesendet: Dienstag, 9 Juni 2020 12:17

>> An: (10)(2e) e) (10)(2e) @bmg.bund.de>

>> Cc: (10)(2e) (10)(2e) @igf.finances.gouv.fr>

>> Betreff: RE: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).

>> Vertraulichkeit: Vertraulich

>> Dear (10)(2e)

>>
>>
>>

>> I understood that we can go directly to AZ in order to discuss directly on our main point of attention on their proposition.

>>

>> Could you give me your contact point at AZ?

>>

>>

>> Thanks for your help

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>> -----Message d'origine-----

>> De : (10)(2e) e) (10)(2e) @bmg.bund.de> Envoyé : lundi 8 juin 2020 17:25 À : (10)(2e)

>> (10)(2e) @pm.gouv.fr>; (10)(2e) @bmg.bund.de>;

>> (10)(2e) @minvws.nl' <(10)(2e) @minvws.nl>; (10)(2e) @minvws.nl' <(10)(2e) @minvws.nl>; (10)(2e) @sanita.it' <(10)(2e) @sanita.it>;

>> (10)(2e) @unicatt.it' <(10)(2e) @unicatt.it>; (10)(2e) @minvws.nl' <(10)(2e) @minvws.nl>;

>> (10)(2e) @igf.finances.gouv.fr' <(10)(2e) @igf.finances.gouv.fr>

>> Cc : 113 BMG <(10)(2e) @bmg.bund.de>; (10)(2e) @bmg.bund.de>; 11 BMG

>> <(10)(2e) @bmg.bund.de>; 1 BMG <(10)(2e) @bmg.bund.de>; (10)(2e) @bmg.bund.de>; 117 BMG

>> <(10)(2e) @bmg.bund.de> Objet : AW: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).

>> Critère de diffusion : Confidentiel

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>>

>> A short update of information from our part:

>>
>>
>>
>> Phone Call with (1 (10)(2e) AZ:

>>
(10)(2e) (10)(2e)

>>
>> (10)(2e) will check the draft contract with her team and inform us tomorrow, if the commission could sign the contract within this week. Indemnity is also a point of concern for her, but she confirmed that Barda/US has a similar approach.

>>
>> Cordially, (10)(2e)

>> Mit freundlichen Grüßen

>> Im Auftrag

>>
(10)(2e)

>> Leiter der Abteilung 1 „Arzneimittel, Medizinprodukte und Biotechnologie“ Bundesministerium für Gesundheit

>> Friedrichstraße 108, 10117 Berlin

>> Postanschrift: 11055 Berlin

>> Tel. (10)(2e)

>> Fax (10)(2e)

>> (10)(2e) @bmg.bund.de <(10)(2e) @bmg.bund.de>

>>
>> [https://urldefense.com/v3/__http://www.bundesgesundheitsministerium.de__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUTfLay0\\$](https://urldefense.com/v3/__http://www.bundesgesundheitsministerium.de__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUTfLay0$)
>> <[https://urldefense.com/v3/__http://www.bundesgesundheitsministerium.de__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUTfLay0\\$](https://urldefense.com/v3/__http://www.bundesgesundheitsministerium.de__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUTfLay0$)>

>>
>> [https://urldefense.com/v3/__http://www.twitter.com/BMG_Bund__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUdfGVy5s\\$](https://urldefense.com/v3/__http://www.twitter.com/BMG_Bund__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUdfGVy5s$)
>> <[https://urldefense.com/v3/__http://www.twitter.com/BMG_Bund__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUdfGVy5s\\$](https://urldefense.com/v3/__http://www.twitter.com/BMG_Bund__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUdfGVy5s$)>

>>
>> [https://urldefense.com/v3/__http://www.facebook.com/BMG.Bund__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUIRiRxl8\\$](https://urldefense.com/v3/__http://www.facebook.com/BMG.Bund__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUIRiRxl8$)
>> <[https://urldefense.com/v3/__http://www.facebook.com/BMG.Bund__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUIRiRxl8\\$](https://urldefense.com/v3/__http://www.facebook.com/BMG.Bund__;!!E1R1dd1bLLODIQ4!RJewxWOWTLnzG_h21oDKepnEBBxyRRbMML9WQHmiv6FcJ8iXBEVQtg_fqjUIRiRxl8$)>

9531527

<< (10)(2e) @ (10)(2e) @bmg.bund.de >>; (10)(2e) -UAL 11 BMG
<< (10)(2e) @bmg.bund.de < (10)(2e) @bmg.bund.de
<< (10)(2e) @ (10)(2e) @bmg.bund.de >>; 117 BMG <(10)(2e)@bmg.bund.de
<< (10)(2e) @bmg.bund.de < (10)(2e) @ (10)(2e) @bmg.bund.de >>
>>
>>
>> Betreff: WG: Draft Term Sheet for Commercial Supply of ChAdOx1 nCoV-19 vaccine (AZD 1222) in Europe (ex-UK).
>>
>>
>> Wichtigkeit: Hoch
>>
>>
>> Vertraulichkeit: Vertraulich
>>
>>
>>
>>
>>
>> Dear colleagues,
>>
>>
>>
>>
>>
>> please find attached the Astra Zeneca draft.
>>
>>
>>
>>
>>
>> Kind regards
>>
>>
>> (10)(2e)
>>
>>
>>
>>
>>
>> Mit freundlichen Grüßen
>>
>>
>> Im Auftrag
>>
>>
>>
>>
>>
>> (10)(2e)
>>
>>
>>
>>
>>

9531527

>>
>>
>>
>>
>>
>>
>> Hier bitte weiter an die Partner und prüfen. Danke!
>>
>>
>>
>>
>>
>>
>>
>> (10)(2e)
>>
>>
>> Bundesministerium für Gesundheit
>>
>>
>>
>> (10)(2e) @bmg.bund.de <(10)(2e) @bmg.bund.de> <(10)(2e) @bmg.bund.de
<(10)(2e) @bmg.bund.de> >
>>
>>
>>
>>
>>
>>
>
>

> This message and any attachments are intended only for use by the named addressee. They may contain confidential or privileged information. If you are not the named recipient of this communication, please contact the sender immediately and delete or destroy the communication without copying it, disclosing its contents to any other person, or using it in any other way.
>
> All services are provided on the basis of an agreement with HOYNG ROKH MONEGIER LLP, a Limited Liability Partnership under the law of England and Wales. The agreement is subject to the General Conditions of HOYNG ROKH MONEGIER LLP of the local office involved. Those General Conditions contain a limitation of liability. A copy of the General Conditions will be forwarded upon request and may also be found at
https://urldefense.com/v3/__http://www.hoyngrokhmonegier.com/__;!E1R1dd1bLLODIQ4!RIJewxWOWTLnzG_h21oDKepnEBBxyRRbMM L9WQHmiv6FcJ8iXBEVQtg_fqIUC0spihcS
<[https://urldefense.com/v3/__http://www.hoyngrokhmonegier.com/__;!E1R1dd1bLLODIQ4!RIJewxWOWTLnzG_h21oDKepnEBBxyRRbMM ML9WQHmiv6FcJ8iXBEVQtg_fqIUBEBYVbs\\$](https://urldefense.com/v3/__http://www.hoyngrokhmonegier.com/__;!E1R1dd1bLLODIQ4!RIJewxWOWTLnzG_h21oDKepnEBBxyRRbMM ML9WQHmiv6FcJ8iXBEVQtg_fqIUBEBYVbs$)>.
>

.....

The information in this e-mail (and any attachments) is intended exclusively for the addressee(s). Any use by a party other than the addressee(s) is prohibited. The information may be confidential in nature and fall under a duty of non-disclosure. If you are not the addressee, please notify the sender and delete this e-mail. KPMG cannot guarantee that e-mail communications are secure and error-free and does not accept any liability for damages resulting from the use of e-mail. Our services and other work are carried out under an agreement of instruction (overeenkomst van opdracht) that is subject to the general terms and conditions of the contracting KPMG firm. These general terms and conditions are available on our website (www.kpmg.nl/algemenevoorwaarden) and will be forwarded upon request.
Agreements with and statements from KPMG are only legally binding upon KPMG if they are confirmed in writing and signed by an authorized person.
